Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

New Recommendations on Immune Tolerance Induction in Hemophilia A

Publish date:: May 15, 2019

Key clinical point: A group of hemophilia experts provided recommendations on immune tolerance induction in patients with hemophilia A with inhibitors.

Major finding: The concurrent use of factor VIII replacement therapy and emicizumab could inhibit bleeding with lower dose immunotolerance treatment strategies.

Study details: Consensus recommendations provided by a nine-member expert committee.

Disclosures: The manuscript was supported by Grifols. The authors reported financial affiliations with Bayer, Bioverativ, CSL Behring, Grifols, Kedrion, Novo Nordisk, Pfizer, and several others.

Citation:

Carcao M et al. Haemophilia. 2019 Apr 29. doi: 10.1111/hae.13762

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Bleeding Disorders

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

Hemochromatosis variants may confer 10-fold higher risk of liver cancer,

Hemophilia, von Willebrand disease do not increase postop complications for ACL reconstruction,

Mouth splints decrease risk of post–dental extraction bleeding in hemophilia,

Low VWF levels or blood group O not linked to intracerebral hemorrhage risk,